The Remdesivir COVID-19 Great Hope Drug Hoax? - Stephen Lendman Despite promising results when COVID-19 patients are treated with chloroquine or hydroxychloroquine (see below) with zinc and, in some cases, azithromycin, a NEW and potential dangerous drug is being foisted on the American public. Apparently insanity knows no bounds. From the Lendman piece (30 April 2020): On Wednesday, news about  Gilead Sciences’ COVID-19 remdesivir drug under development sent the company’s stock price and overall US stock market soaring, the same for other equity markets. Yet no evidence shows that the drug is effective in treating the coronavirus. No matter. Establishment media reports hailed the experimental drug. “The stock market rallied after promising news about an antiviral drug,” the NYT reported. The Washington Post headlined: “Hopes rise for experimental drug therapy for covid-19.” WSJ: “Global Markets Follow US Stocks Higher…on promising news on a coronavirus treatment.” CNN reported that the “FDA will reportedly authorize use of remdesivir for Covid-19 after trial shows ‘positive effect’ on recovery time.” According to Bloomberg News, “Gilead’s CEO says over 50,000 remdesivir courses are ready to ship.” Reuters reported “(t)he top US infectious disease official (Anthony Fauci) said Gilead Sciences Inc’s experimental antiviral drug remdesivir will become the standard of care for COVID-19 after early clinical trial results on Wednesday showed it helped patients recover more quickly from the illness caused by the coronavirus.” Other establishment media reports were similar to the above — hailing an experimental drug that may prove ineffective or harmful to human health once more about it is known. https://stephenlendman.org/2020/04/the-remdesivir-covid-19-great-hope-drug-hoax/ From: Hydroxychloroquine Has about 90 Percent Chance of Helping COVID-19 Patients (28 April 2020) To date, the total number of reported patients treated with HCQ, with or without zinc and the widely used antibiotic azithromycin, is 2,333, writes AAPS (Association of American Physicians and Surgeons), in observational data from China, France, South Korea, Algeria, and the U.S. Of these, 2,137 or 91.6 percent improved clinically. There were 63 deaths, all but 11 in a single retrospective report from the Veterans Administration where the patients were severely ill. The antiviral properties of these drugs have been studied since 2003. Particularly when combined with zinc, they hinder viral entry into cells and inhibit replication. They may also prevent overreaction by the immune system, which causes the cytokine storm responsible for much of the damage in severe cases, explains AAPS. HCQ is often very helpful in treating autoimmune diseases such as lupus and rheumatoid arthritis. Additional benefits shown in some studies, AAPS states, is to decrease the number of days when a patient is contagious, reduce the need for ventilators, and shorten the time to clinical recovery. https://aapsonline.org/hcq-90-percent-chance/